PPARG and type 2 diabetes mellitus: Correspondingly, thiazolidinedione compounds (TZDs), a class of insulin-sensitizing drug used in the treatment of type 2 diabetes, and a synthetic PPARγ ligand improve glucose tolerance, which may indirectly ameliorate the progression of chronic kidney disease (CKD).